Spruce Biosciences (SPRB) Capital Expenditures (2019 - 2026)

Spruce Biosciences (SPRB) posted quarterly Capital Expenditures of $10000.0 for Q1 2026, up 42.86% quarter-over-quarter from $7000.0 in Q3 2023.

Spruce Biosciences (SPRB) Capital Expenditures (2019 - 2026) Analysis & Trends

Spruce Biosciences (SPRB) has reported Capital Expenditures for 6 consecutive years, with $10000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Capital Expenditures changed N/A year-over-year to $10000.0; the TTM figure through Mar 2026 stood at $10000.0 (up 42.86% YoY), while the FY2023 annual figure was $7000.0, down 12.5% from the prior year.
Capital Expenditures climbed to $10000.0 in Q1 2026 per SPRB's latest filing, from $7000.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $10000.0 in Q1 2026 and bottomed at $2000.0 in Q3 2022.
Historically, Capital Expenditures has averaged $6333.3 across 3 years, with a median of $7000.0 in 2023.
Annual changes were most pronounced in 2022 — Capital Expenditures tumbled 96.92% — and 2023, when it soared 250.0%.
Spruce Biosciences' Capital Expenditures stood at $2000.0 in 2022, then jumped by 250.0% to $7000.0 in 2023, then jumped by 42.86% to $10000.0 in 2026.
Business Quant data shows SPRB's Capital Expenditures at $10000.0 in Q1 2026, $7000.0 in Q3 2023, and $2000.0 in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	34.68 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	6.26 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	251.02 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-73.57 Mn
10	Spruce Biosciences	127.07 Mn	127.07 Mn	-	135,000.00

Download Data